Education presentation: Perinatal substance use: neonatalAdmit to SCN and Commence pharmacotherapy...

Translating evidence into best clinical practiceTranslating evidence into best clinical practice

Department of Health

Perinatal substance use: neonatal

45 minutes

Towards CPD Hours

Queensland Clinical Guideline: Perinatal substance use: neonatal 2

References: The Queensland Clinical Guideline: Perinatal substance use: neonatal is the primary reference for this package. Recommended citation: Queensland Clinical Guidelines. Perinatal substance use: neonatal: Clinical guideline education presentation E16.38-1-V2-R21. Queensland Health. 2016. Disclaimer: This presentation is an implementation tool and should be used in conjunction with the published guideline. This information does not supersede or replace the guideline. Consult the guideline for further information and references. Feedback and contact details: M: GPO Box 48 Brisbane QLD 4001 | E: Guidelines@health.qld.gov.au | URL: www.health.qld.gov.au/qcg Funding:

Queensland Clinical Guidelines is supported by the Queensland Health, Healthcare Innovation and Research Branch. Copyright: © State of Queensland (Queensland Health) 2018 This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 3.0 Australia licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the Queensland Clinical Guidelines Program, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en For further information contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email guidelines@health.qld.gov.au, phone (+61) 07 3131 6777. For permissions beyond the scope of this licence contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au, phone (07) 3234 1479. Images are property of State of Queensland (Queensland Health) unless otherwise cited.

Neonatal abstinence syndrome (NAS)

• Syndrome of drug withdrawal with non-specific signs in a baby following exposure to a variety of substances inutero

Queensland Clinical Guideline: Perinatal substance use: neonatal 3

Neonatal withdrawal may be caused by inutero exposure to:

• Opioids • Benzodiazepines, • Selective Serotonin Reuptake Inhibitors

(SSRIs) • Alcohol and tobacco • Amphetamines

Queensland Clinical Guideline: Perinatal substance use: neonatal 4

Resuscitation

• Usual neonatal resuscitation as required • Do not administer Naloxone

◦ In the neonatal period if baby has had inutero exposure to opioids

◦ May precipitate severe rapid onset of seizures

Queensland Clinical Guideline: Perinatal substance use: neonatal 5

Symptomatic baby

• Clinical assessment and examination • Review maternal history of licit/illicit

substances • Discuss substance use with woman

◦ May be undisclosed • Consider admission to

special care nursery

Queensland Clinical Guideline: Perinatal substance use: neonatal 6

Symptomatic baby

• Supportive care • Postnatal observations • Finnegan scores

◦ Score the average of baby’s behaviour since last scored

Queensland Clinical Guideline: Perinatal substance use: neonatal 7

Clinical signs

• Suspect NAS if baby: ◦ Unsettled ◦ Irritable ◦ Has high pitched cry ◦ Jittery or has tremors ◦ Does not feed well +/- diarrhoea

• Signs may be caused by concurrent illness

Queensland Clinical Guideline: Perinatal substance use: neonatal 8

Onset of withdrawal

• Heroin: between 24 and 72 hours of age (may be earlier)

• Methadone/Buprenorphine: between 72 hours to 7 days

• SSRI: Day 2 up to day 5–7

Queensland Clinical Guideline: Perinatal substance use: neonatal 9

Differential diagnosis

• Infection • Hypoglycaemia • Hypocalcaemia • Metabolic disorders

Queensland Clinical Guideline: Perinatal substance use: neonatal 10

Clinical examination

• Conduct a full examination • Consider concurrent illness • Review risk factors for neonatal sepsis • Investigate to exclude infection or

metabolic disturbance • Treat any identified illness

Queensland Clinical Guideline: Perinatal substance use: neonatal 11

Preterm babies

• Less severe NAS related to: ◦ Developmental immaturity of specific opiate

receptors/neurotransmitter function ◦ Reduced exposure time ◦ Reduced fatty deposits of drugs

Queensland Clinical Guideline: Perinatal substance use: neonatal 12

Inter-hospital transfer

• If appropriate, transfer the antenatal woman to a higher level facility or

• If required, transfer woman and baby after birth to higher level facility

Queensland Clinical Guideline: Perinatal substance use: neonatal 13

Management of substance withdrawal

• Use non-pharmacological management as first line treatment

• Use pharmacological treatment if withdrawal not adequately controlled

Queensland Clinical Guideline: Perinatal substance use: neonatal 14

Supportive/non-pharmacological care

• Support rooming-in • Minimise hunger─encourage breastfeeding • Early response to baby cues • Decrease environmental stimuli (e.g. light

and sound) • Cluster care─avoid over-stimulation

Queensland Clinical Guideline: Perinatal substance use: neonatal 15

• Individual risk-benefit analysis • Breastfeeding not recommended if:

◦ HIV positive ◦ Using, alcohol, amphetamines, heroin, cocaine

• Encourage/support breastfeeding where possible

• Develop feeding safety plan with woman

Feeding

Queensland Clinical Guideline: Perinatal substance use: neonatal 16

Breast milk

• Analgesic for baby • Soothes agitated baby • Helps meet higher caloric requirements • Helps reduce stress response and

increased vagal tone in woman

Queensland Clinical Guideline: Perinatal substance use: neonatal 17

Formula feeding

• May be primary source of nutrition • Usual education re:

◦ Preparation, ◦ Storage, ◦ Equipment cleaning ◦ Transport

Queensland Clinical Guideline: Perinatal substance use: neonatal 18

Finnegan tool

• Most widely used assessment of opioid withdrawal in term babies

• May be used to aid assessment of other substance withdrawal

• Requires staff training and auditing to ensure reliability and scoring consistency

• Ensure inter- and intra- observer validation of scoring

Queensland Clinical Guideline: Perinatal substance use: neonatal 19

Finnegan scoring

• Start within 2 hours of birth • Score 4–6 hourly 30–60 minutes after feeds • Assign only one score for each sign in each

of the three sections • Score reflects behaviour since previous

assessment • Do not disturb baby to assess signs • Make allowances if baby preterm

Queensland Clinical Guideline: Perinatal substance use: neonatal 20

Queensland Clinical Guideline: Perinatal substance use: neonatal 21

SYSTEM SIGN SCORE

Cent

ral n

ervo

us s

yste

m d

istu

rban

ces

Excessive high pitched cry Continuous high pitched cry

2 3

Sleeps < 1 hour after feeding Sleeps < 2 hours after feeding Sleeps < 3 hours after feeding

3 2 1

Hyperactive Moro reflex Markedly hyperactive Moro reflex

2 3

Mild tremors disturbed Moderate–severe tremors disturbed Mild tremors undisturbed Moderate–severe tremors undisturbed

1 2 3 4

Increased muscle tone 2

Excoriation 1

Myoclonic jerks 3

Generalised convulsions 5 G

astro

inte

stin

al

dist

urba

nces

Excessive sucking 1

Poor feeding 2

Regurgitation Projectile vomiting

2 3

Loose stools Watery stools

2 3

Resp

irato

ry/v

asom

otor

di

stur

banc

es

Sweating 1

Fever 37.3 to 38.3 °C Fever 38.4 °C and above

1 2

Frequent yawning > 3–4 in half hour 1

Mottling 1

Nasal stuffiness 1

Sneezing > 3–4 in half hour 1

Nasal flaring 2

Respiratory rate > 60/minute Respiratory rate > 60/minute and retractions

1 2

TOTAL SCORE

SCORER’S INITIALS

Finn

egan

Sco

re

2 consecutive scores ≥ 12 OR

3 consecutive scores average ≥ 8

Queensland Clinical Guideline: Perinatal substance use: neonatal 22

Admit to SCN and

Commence pharmacotherapy

Scoring

Morphine

• Opiate of choice • Less likely to have seizures • Less likely to require treatment with

second line agent • Duration of treatment may be less

Queensland Clinical Guideline: Perinatal substance use: neonatal 23

Phenobarbitone

• Use as an adjunct to Morphine when NAS not controlled

• Initial treatment where substance/s used by woman: ◦ Unknown or polysubstance ◦ Alcohol (intoxication at birth) ◦ SSRI or sedatives (Benzodiazepines)

Queensland Clinical Guideline: Perinatal substance use: neonatal 24

Paediatric review

• Early and daily consultation • When showing signs of NAS • If commencing Morphine or Phenobarbitone • When receiving maximum dose of

medication • Exclusion of other causes

not possible

Queensland Clinical Guideline: Perinatal substance use: neonatal 25

Discharge planning

• Assess for safe discharge of baby • Minimum 5 days in hospital for opioid

withdrawing baby • Minimum 3 days in hospital for SSRI

exposed baby

Queensland Clinical Guideline: Perinatal substance use: neonatal 26

Discharge plan

• Feeding plan • Home medication if appropriate • Child safety plan • Parent education • Immunisations • Community referrals & paediatric follow up

Queensland Clinical Guideline: Perinatal substance use: neonatal 27

Contraindications to discharge

• Court order • Excessive weight loss • Less than 5 days old if opioid exposure • Suspected neglect or abuse • Suspected home violence • Ongoing assessment of withdrawal

Queensland Clinical Guideline: Perinatal substance use: neonatal 28

Relative contraindications to discharge

• Woman has limited ability to care for baby • Inadequate home support/refusal to

accept help • Problematic drug or polysubstance use • Erratic behaviour/mental health

issues/psychological distress

Queensland Clinical Guideline: Perinatal substance use: neonatal 29

Child protection issues

• Increased risk of: ◦ Poor health and wellbeing outcomes ◦ Exposure to maternal high risk behaviours ◦ Being subjected to social issues

• Not all babies have involvement of child protection services

Queensland Clinical Guideline: Perinatal substance use: neonatal 30

Child safety

• Raise concerns if: ◦ Continued IV or other illicit drug use ◦ Suspected baby neglect ◦ Domestic violence ◦ Non-compliance with management ◦ Other issues identified

Queensland Clinical Guideline: Perinatal substance use: neonatal 31

Immunisation

Queensland Clinical Guideline: Perinatal substance use: neonatal 32

Hepatitis B surface antigen (HBsAg)

positive

Hepatitis B status unknown and urgent

serology not available

Hepatitis B immunoglobulin within 12 hours of birth and

Hepatitis B vaccination within 24 hours of birth

OR

Administer to baby:

If woman is: